Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04869787 · ClinicalTrials.gov registry record · NA
A Multi-Center Study of a SCD for Immunomodulatory Dysregulation in Pediatric AKI
A NA study, sponsored by Children's Hospital Medical Center, Cincinnati.
- Terminated
- Registry status
- NA
- Development phase
- 7
- Enrollment target
NCT04869787 is a NA study that was terminated before completion, run by Children's Hospital Medical Center, Cincinnati. The registered enrollment target is 7 participants.
The verdict
NCT04869787, a NA study, was terminated before completion, sponsored by Children's Hospital Medical Center, Cincinnati.
- TERMINATED
- Registry status
- NA
- Development phase
- 7 participants
- Enrollment target
Study Summary
The SCD PED-02 trial is examining the safety and efficacy of the Selective Cytopheretic Device (SCD) in treating pediatric acute kidney injury (AKI). AKI promotes a systemic inflammatory response syndrome (SIRS) which results in systemic microvascular damage and, if severe, multi-organ dysfunction. Activated circulating leukocytes play a central role in this process. The SCD is a synthetic membrane with the ability to bind activated leukocytes and, when used in a continuous renal replacement therapy (CRRT) extracorporeal circuit in the presence of regional citrate anticoagulation, modulates inflammation. The SCD PED-02 study will test the primary hypothesis that up to ten sequential 24-hour SCD treatments in pediatric patients with AKI will be completed safely and improve survival compared to historical controls who received CRRT alone.
Interventions
- DEVICE Selective Cytopheretic Device
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2021-05-17 |
| Est. Completion | 2023-10-27 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04869787
The ClinicalTrials.gov registry entry for NCT04869787 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's Hospital Medical Center, Cincinnati, which has 571 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Selective Cytopheretic Device is the first listed.
NCT04869787 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04869787 about?
NCT04869787 is a clinical study titled "A Multi-Center Study of a SCD for Immunomodulatory Dysregulation in Pediatric AKI". The SCD PED-02 trial is examining the safety and efficacy of the Selective Cytopheretic Device (SCD) in treating pediatric acute kidney injury (AKI). AKI promotes a systemic inflammatory response syndrome (SIRS) which results in systemic microvascular damage and, if severe, multi-organ dysfunction. ...
What is the current status of trial NCT04869787?
This trial is currently terminated. It is a NA study. The enrollment target is 7 participants. The study started on 2021-05-17. Estimated completion is 2023-10-27.
What interventions are being tested in trial NCT04869787?
The interventions under investigation include: Selective Cytopheretic Device (DEVICE).
Who is sponsoring clinical trial NCT04869787?
This trial is sponsored by Children's Hospital Medical Center, Cincinnati, which has 571 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.